drug: oxymorphone
*
- Clinical class: narcotic analgesic
- Action: opioid agonist
- Chemical class: semi-synthetic opioid
- CSA schedule: II
- DEA number: 9652
- Route of administration: injection, oral, suppository
- Associated with (substance-related): disorders
U.S. Preparations:
- Numorphan® (Endo
Pharmaceuticals Inc.) FDA approved indications:
1.28.1959 (injection) relief of moderate to severe pain
4.2.1959 (suppository) relief of moderate to severe pain
U.S. Prescribing information
- Opana® (Endo
Pharmaceuticals Inc.) FDA approved indications:
6.22.2006 relief of moderate to severe acute pain where the use of an opioid is appropriate - Opana® ER
(Endo Pharmaceuticals Inc.) FDA approved indications:
6.22.2006 relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time
U.S. Prescribing information - Opana®
Injection (Endo
Pharmaceuticals Inc.) FDA approved indications:
10.16.2006 (date of labeling revision: previously marketed as Numorphan®) relief of moderate to severe pain; preoperative medication, for support of anesthesia, and for relief of anxiety in patients with dyspnea associated with pulmonary edema secondary to acute left ventricular dysfunction
U.S. Prescribing information
*Molecule graphic courtesy of Steve Chapman